Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

| More on:
a group of people stand examining a large glowing cystral ball held in the hands of one of the group members while the others regard it with various expressions of wonder, curiousity and scepticism.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone right now:

CSL Ltd (ASX: CSL)

According to a note out of Goldman Sachs, its analysts have initiated coverage on this biotechnology giant's shares with a buy rating and $325.40 price target. Goldman Sachs is feeling very positive about CSL's outlook and is forecasting double-digit immunoglobulin (IG) growth each year through to FY 2028. It expects this to be underpinned by low penetration and ~100 basis points year on year market share gains. Another positive is that Goldman highlights that its channel checks indicate that CSL's competitive advantages are intact, with the expansion in fractionation capacity set to enhance CSL's superior cost profile and supply reliability. This is expected to lead to margin expansion and strong earnings growth in the coming years. The CSL share price is trading at $276.86 on Friday.

NextDC Ltd (ASX: NXT)

A note out of Morgans reveals that its analysts have retained their add rating on this data centre operator's shares with a slightly trimmed price target of $20.00. Morgans has been updating its financial model ahead of earnings season. After factoring in its recent capital raising, the broker has trimmed its price target. However, it remains very positive on the company and its outlook. Morgans continues to believe that NextDC is well-placed to benefit from the structural growth in demand for data centres. The NextDC share price is fetching $15.58 at the time of writing.

ResMed Inc. (ASX: RMD)

Another note out of Goldman Sachs reveals that its analysts have initiated coverage on this sleep disorder treatment company's shares with a buy rating and $48.90. According to the note, the broker believes that ResMed is well-positioned to achieve the top end of is FY 2030 revenue financial target. This implies a compound annual growth rate of 8.9% between FY 2025 and FY 2030. It expects this to be underpinned by robust Continuous Airway Pressure Therapy (CPAP) patient growth, assisted by growing awareness on Obstructive Sleep Apnoea (OSA), market share gains, particularly in OSA masks, and operating margin expansion driven by product mix and solid cost management. The ResMed share price is trading at $38.24 on Friday morning.

Motley Fool contributor James Mickleboro has positions in CSL, Nextdc, and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goldman Sachs Group, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

How much upside does Macquarie expect for Steadfast Group shares?

The broker has given its verdict on this blue chip.

Read more »

Female miner standing smiling in a mine.
Broker Notes

Why Macquarie predicts Pilbara Minerals shares could surge 71%

Macquarie forecasts a big rebound ahead for Pilbara Minerals shares. Let’s find out why.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Broker Notes

The smartest Australian stocks to buy with $250 right now

$250 to invest? Check out these stocks that brokers rate as buys.

Read more »

A woman wearing dark clothing and sporting a few tattoos and piercings holds a phone and a takeaway coffee cup as she strolls under the Sydney Harbour Bridge which looms in the background.
Broker Notes

1 magnificent Aussie stock down 23% to buy and hold forever

Let's see why this could be a top share to buy while it is down.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Bell Potter says this ASX 200 stock can rise 100%+

Let's see which stock the broker is tipping as a buy to clients.

Read more »

Man sitting in a plane looking through a window and working on a laptop.
Broker Notes

Macquarie tips 28% upside for this ASX All Ords tech stock

Let's see what the broker is saying about this growth stock.

Read more »

A man looking at his laptop and thinking.
Broker Notes

Up 17% in 2025, how much more upside does Macquarie tip for Metcash shares?

Following Tuesday’s merger and earnings news, Macquarie changed its rating for Metcash shares.

Read more »